BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 27635946)

  • 1. Tubulocystic Carcinoma of the Kidney With Poorly Differentiated Foci: A Frequent Morphologic Pattern of Fumarate Hydratase-deficient Renal Cell Carcinoma.
    Smith SC; Trpkov K; Chen YB; Mehra R; Sirohi D; Ohe C; Cani AK; Hovelson DH; Omata K; McHugh JB; Jochum W; Colecchia M; Amin M; Divatia MK; Hes O; Menon S; Werneck da Cunha I; Tripodi S; Brimo F; Gill AJ; Osunkoya AO; Magi-Galluzzi C; Sibony M; Williamson SR; Nesi G; Picken MM; Maclean F; Agaimy A; Cheng L; Epstein JI; Reuter VE; Tickoo SK; Tomlins SA; Amin MB
    Am J Surg Pathol; 2016 Nov; 40(11):1457-1472. PubMed ID: 27635946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fumarate Hydratase-deficient Renal Cell Carcinoma Is Strongly Correlated With Fumarate Hydratase Mutation and Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome.
    Trpkov K; Hes O; Agaimy A; Bonert M; Martinek P; Magi-Galluzzi C; Kristiansen G; Lüders C; Nesi G; Compérat E; Sibony M; Berney DM; Mehra R; Brimo F; Hartmann A; Husain A; Frizzell N; Hills K; Maclean F; Srinivasan B; Gill AJ
    Am J Surg Pathol; 2016 Jul; 40(7):865-75. PubMed ID: 26900816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reappraisal of Morphologic Differences Between Renal Medullary Carcinoma, Collecting Duct Carcinoma, and Fumarate Hydratase-deficient Renal Cell Carcinoma.
    Ohe C; Smith SC; Sirohi D; Divatia M; de Peralta-Venturina M; Paner GP; Agaimy A; Amin MB; Argani P; Chen YB; Cheng L; Colecchia M; Compérat E; Werneck da Cunha I; Epstein JI; Gill AJ; Hes O; Hirsch MS; Jochum W; Kunju LP; Maclean F; Magi-Galluzzi C; McKenney JK; Mehra R; Nesi G; Osunkoya AO; Picken MM; Rao P; Reuter VE; de Oliveira Salles PG; Schultz L; Tickoo SK; Tomlins SA; Trpkov K; Amin MB
    Am J Surg Pathol; 2018 Mar; 42(3):279-292. PubMed ID: 29309300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cancer: recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry.
    Chen YB; Brannon AR; Toubaji A; Dudas ME; Won HH; Al-Ahmadie HA; Fine SW; Gopalan A; Frizzell N; Voss MH; Russo P; Berger MF; Tickoo SK; Reuter VE
    Am J Surg Pathol; 2014 May; 38(5):627-37. PubMed ID: 24441663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of succinate dehydrogenase and fumarate hydratase-deficient renal cell carcinoma based on immunohistochemical screening with SDHA/SDHB and FH/2SC.
    Gupta S; Swanson AA; Chen YB; Lopez T; Milosevic D; Kipp BR; Leibovich BC; Thompson RH; Herrera-Hernandez L; Cheville JC; Jimenez RE
    Hum Pathol; 2019 Sep; 91():114-122. PubMed ID: 31299266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fumarate hydratase-deficient renal cell carcinoma: A clinicopathological study of seven cases including hereditary and sporadic forms.
    Kuroda N; Tsutsui M; Iguchi M; Nobuoka E; Uehara T; Sonobe Y; Morinaga Y; Shibuya S; Oda W; Yanai H; Kawada C; Karashima T; Yamasaki I; Inoue K; Nagashima Y
    Ann Diagn Pathol; 2020 Dec; 49():151599. PubMed ID: 32977234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Clinicopathological and Molecular Analysis of Fumarate Hydratase (FH)-deficient Renal Cell Carcinomas with Heterogeneous Loss of FH Expression.
    Anderson WJ; Tsai HK; Sholl LM; Hirsch MS
    Int J Surg Pathol; 2022 Sep; 30(6):606-615. PubMed ID: 35048731
    [No Abstract]   [Full Text] [Related]  

  • 8. Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status.
    Bardella C; El-Bahrawy M; Frizzell N; Adam J; Ternette N; Hatipoglu E; Howarth K; O'Flaherty L; Roberts I; Turner G; Taylor J; Giaslakiotis K; Macaulay VM; Harris AL; Chandra A; Lehtonen HJ; Launonen V; Aaltonen LA; Pugh CW; Mihai R; Trudgian D; Kessler B; Baynes JW; Ratcliffe PJ; Tomlinson IP; Pollard PJ
    J Pathol; 2011 Sep; 225(1):4-11. PubMed ID: 21630274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemistry for 2-Succinocysteine (2SC) and Fumarate Hydratase (FH) in Cutaneous Leiomyomas May Aid in Identification of Patients With HLRCC (Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome).
    Buelow B; Cohen J; Nagymanyoki Z; Frizzell N; Joseph NM; McCalmont T; Garg K
    Am J Surg Pathol; 2016 Jul; 40(7):982-8. PubMed ID: 26945337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pattern multiplicity and fumarate hydratase (FH)/S-(2-succino)-cysteine (2SC) staining but not eosinophilic nucleoli with perinucleolar halos differentiate hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinomas from kidney tumors without FH gene alteration.
    Muller M; Guillaud-Bataille M; Salleron J; Genestie C; Deveaux S; Slama A; de Paillerets BB; Richard S; Benusiglio PR; Ferlicot S
    Mod Pathol; 2018 Jun; 31(6):974-983. PubMed ID: 29410489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Morphology and Immunohistochemistry for 2SC and FH Aid in Detection of Fumarate Hydratase Gene Aberrations in Uterine Leiomyomas From Young Patients.
    Joseph NM; Solomon DA; Frizzell N; Rabban JT; Zaloudek C; Garg K
    Am J Surg Pathol; 2015 Nov; 39(11):1529-39. PubMed ID: 26457356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Morphologic and molecular characteristics of uterine leiomyomas in hereditary leiomyomatosis and renal cancer (HLRCC) syndrome.
    Sanz-Ortega J; Vocke C; Stratton P; Linehan WM; Merino MJ
    Am J Surg Pathol; 2013 Jan; 37(1):74-80. PubMed ID: 23211287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of prospective pathologic evaluation to inform clinical genetic testing for hereditary leiomyomatosis and renal cell carcinoma.
    Kopp RP; Stratton KL; Glogowski E; Schrader KA; Rau-Murthy R; Russo P; Coleman JA; Offit K
    Cancer; 2017 Jul; 123(13):2452-2458. PubMed ID: 28171700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clues to recognition of fumarate hydratase-deficient renal cell carcinoma: Findings from cytologic and limited biopsy samples.
    Shyu I; Mirsadraei L; Wang X; Robila V; Mehra R; McHugh JB; Chen YB; Udager AM; Gill AJ; Cheng L; Amin MB; Lin O; Smith SC
    Cancer Cytopathol; 2018 Dec; 126(12):992-1002. PubMed ID: 30339328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detailed Morphologic and Immunohistochemical Characterization of Myomectomy and Hysterectomy Specimens From Women With Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome (HLRCC).
    Chan E; Rabban JT; Mak J; Zaloudek C; Garg K
    Am J Surg Pathol; 2019 Sep; 43(9):1170-1179. PubMed ID: 31162287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of Clinicopathological, immunohistochemistry and molecular detection in the diagnosis of fumarate hydratase-deficient uterine leiomyomas.
    Zhang X; Wang C; Shen D
    Pathol Res Pract; 2024 Jan; 253():154916. PubMed ID: 38029712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel morphological and genetic features of fumarate hydratase deficient renal cell carcinoma in HLRCC syndrome patients with a tailored therapeutic approach.
    Wyvekens N; Valtcheva N; Mischo A; Helmchen B; Hermanns T; Choschzick M; Hötker AM; Rauch A; Mühleisen B; Akhoundova D; Weber A; Moch H; Rupp NJ
    Genes Chromosomes Cancer; 2020 Nov; 59(11):611-619. PubMed ID: 32537760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fumarate hydratase deficient renal cell carcinoma and fumarate hydratase deficient-like renal cell carcinoma: Morphologic comparative study of 23 genetically tested cases.
    Pivovarčíková K; Martínek P; Trpkov K; Alaghehbandan R; Magi-Galluzzi C; Mundo EC; Berney D; Suster S; Gill A; Rychlý B; Michalová K; Pitra T; Hora M; Michal M; Hes O
    Cesk Patol; 2019; 55(4):244-249. PubMed ID: 31842557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers.
    Muller M; Ferlicot S; Guillaud-Bataille M; Le Teuff G; Genestie C; Deveaux S; Slama A; Poulalhon N; Escudier B; Albiges L; Soufir N; Avril MF; Gardie B; Saldana C; Allory Y; Gimenez-Roqueplo AP; Bressac-de Paillerets B; Richard S; Benusiglio PR
    Clin Genet; 2017 Dec; 92(6):606-615. PubMed ID: 28300276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fumaratehydratase-deficient renal cell carcinoma: a clinicopathological and molecular study of 13 cases.
    Pan X; Zhang M; Yao J; Zeng H; Nie L; Gong J; Chen X; Xu M; Zhou Q; Chen N
    J Clin Pathol; 2019 Nov; 72(11):748-754. PubMed ID: 31262952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.